Nikhil Prasad Fact checked by:Thailand Medical News Team Jun 10, 2024 5 months, 1 week, 4 days, 20 hours, 7 minutes ago
Cancer-News: Recent studies have brought new hope to the fight against pancreatic neuroendocrine neoplasms (panNENs), a rare but challenging type of cancer. Researchers at Kanazawa University in Japan have been investigating the effects of metformin, a common antidiabetic drug, on these tumors. Their findings coved in this
Cancer News report, suggest that metformin may significantly inhibit the growth and survival of panNEN cells by altering mitochondrial function and activating key cellular pathways.
Metformin: A Surprising New Hope for Pancreatic Tumor Treatment
Understanding Pancreatic Neuroendocrine Tumors
Pancreatic neuroendocrine tumors represent a small fraction of pancreatic cancers, making up about 1-2% of cases. Despite their relative rarity and generally better prognosis compared to exocrine pancreatic cancers, panNENs still pose a significant risk of recurrence, even in low-grade cases. The increasing incidence of panNENs, particularly among younger populations, underscores the need for effective, long-term treatment strategies.
Metformin: Beyond Diabetes Management
Metformin is widely recognized for its role in managing type 2 diabetes. It works primarily by reducing glucose production in the liver and increasing insulin sensitivity. However, its potential benefits extend beyond diabetes management.
Epidemiological studies have shown that diabetic patients treated with metformin have lower rates of cancer incidence and mortality compared to those on other treatments.
The Study: Metformin's Impact on PanNEN Cells
The research conducted by Dr Shogo Maruzen and colleagues at Kanazawa University aimed to delve deeper into how metformin affects panNEN cells at the molecular level. Using the human panNEN cell line QGP-1 and the rat insulinoma cell line RIN-m, they conducted a series of experiments to assess cell metabolism, viability, and proliferation in response to metformin treatment.
Key Findings
-Suppression of Mitochondrial Respiration: The study revealed that metformin significantly decreases the oxygen consumption rate (OCR) in both QGP-1 and RIN-m cells, indicating a suppression of mitochondrial respiration. This effect was observed both immediately and after prolonged exposure to metformin, suggesting that the drug disrupts the cells' energy production processes.
-Activation of AMPK: Metformin was found to activate adenosine monophosphate-activated protein kinase (AMPK) in a dose-dependent manner. AMPK is a crucial enzyme in cellular energy homeostasis, and its activation leads to the inhibition of pathways that promote cell growth and proliferation. The study showed increased levels of phosphorylated AMPK and decreased expression of cyclin D1, a protein involved in cell cycle regulation.
-Inhibition of Cell Proliferation: Cell proliferation assays demonstrated that metformin effectively
inhibits the growth of QGP-1 and RIN-m cells. This antiproliferative effect was dose-dependent, with higher concentrations of metformin leading to more significant suppression of cell growth.
-Potential Mechanisms: The researchers hypothesized that the antitumor effects of metformin are primarily mediated through the inhibition of mitochondrial complex I activity and the subsequent activation of AMPK. By disrupting the cells' energy production and growth signaling pathways, metformin induces a metabolic stress that cancer cells find difficult to overcome.
Implications and Future Directions
The findings from this study provide a strong foundation for considering metformin as a potential therapeutic agent for pancreatic neuroendocrine tumors. However, several questions remain unanswered. For instance, the exact molecular mechanisms through which metformin exerts its effects on panNEN cells need further elucidation. Additionally, while the in vitro results are promising, clinical trials are necessary to determine the efficacy and safety of metformin in patients with panNENs.
Conclusion
Metformin, a drug long used for managing diabetes, is emerging as a potential new ally in the fight against pancreatic neuroendocrine tumors. By targeting mitochondrial function and key cellular pathways, metformin shows promise in inhibiting tumor growth and improving patient outcomes. As research continues, metformin may soon join the arsenal of treatments available for this challenging type of cancer, offering hope to patients and clinicians alike.
The study findings were published in the peer reviewed journal: Onco.
https://www.mdpi.com/2673-7523/4/2/7
For the latest
Cancer News, keep on logging to Thailand Medical News.
Read Also:
https://www.thailandmedical.news/news/university-of-nebraska-study-finds-that-micrornas-play-key-roles-in-pancreatic-cancer
https://www.thailandmedical.news/news/herbs-and-phytochemicals-hong-kong-researchers-find-that-the-phytochemical-isoliquiritigenin-from-licorice-can-inhibit-pancreatic-cancer-progression
